Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

Blood Cancer J. 2023 Feb 24;13(1):30. doi: 10.1038/s41408-023-00803-z.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Flow Cytometry / methods
  • Humans
  • Mass Spectrometry / methods
  • Multiple Myeloma*
  • Neoplasm, Residual

Associated data

  • ClinicalTrials.gov/NCT01191060